Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593600 | 1.00 | TRPA1 (0.52) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL4071499 | 0.80 | TRPA1 (0.48) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL4071497 | 0.80 | TRPA1 (0.48) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL9325711 | 0.78 | TRPA1 (0.50) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL185170 | 0.76 | TRPA1 (0.50) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL21331657 | 0.76 | TRPA1 (0.50) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL22206809 | 0.76 | TRPA1 (0.48) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL9222442 | 0.75 | TRPA1 (0.64) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL9719434 | 0.74 | TRPA1 (0.47) | TRPA1ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL6860167 | 0.74 | TRPA1 (0.47) | TRPA1ADRA2CKDM4ELMNAADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465850-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2012-06-20 | — | — | EP | claimed |
| EP-1989185-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | claimed |
| WO-2007100851-A1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | claimed |
| EP-2465850-B1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2016-11-23 | — | — | EP | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| EP-1989185-B1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| EP-2465850-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| EP-1989185-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100851-A1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | MAOB, MAOA, HTR1B | TRPA1 4661/4885ADRA2C 196/4885KDM4E 731/4885 |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | MAOB, MAOA, HTR1B | TRPA1 4184/4885ADRA2C 368/4885KDM4E 844/4885 |
| US-20070203154-A1 | Therapeutic Compounds | MAOB, MAOA, HTR1B | TRPA1 4661/4885ADRA2C 196/4885KDM4E 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.